Nona Biosciences and Pfizer Have Entered Into a Worldwide License Agreement for HBM9033, an Antibody-drug Conjugate (ADC) Targeting MSLN
Friday, December 15, 2023
Nona Biosciences, a global biotechnology company specializing in a comprehensive "Idea to IND" (I to ITM) solution covering target validation, antibody discovery, and preclinical research, has recently disclosed an exclusive license agreement with Pfizer Inc. This collaboration focuses on the global clinical development and commercialization of Nona Biosciences' antibody-drug conjugate (ADC), HBM9033, which targets MSLN.
According to the agreement's terms, Nona Biosciences is set to receive up to $53 million in upfront and near-term payments, with the potential for additional payments reaching up to $1.05 billion upon achieving specific development and commercial milestones. Additionally, Nona Biosciences stands to earn tiered royalties on net sales ranging from high single digits to high teens.
Expressing enthusiasm about the collaboration with Pfizer, Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences, highlighted Pfizer's commitment to developing impactful cancer medicines. Wang sees this agreement as a significant milestone for Nona Biosciences, showcasing the advancement of their proprietary Harbour Mice® platform and the ADC ecosystem. This partnership with Pfizer expands Nona's global network of collaborations, strengthening the scientific and commercial value of their technology platforms.
HBM9033, the focal point of this collaboration, is an ADC drug designed to target human MSLN, a tumor-associated antigen found in various solid tumors. The fully human monoclonal antibody (mAb) in HBM9033, derived from the Harbour Mice® platform, exhibits well-tuned properties, demonstrating reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. This unique design ensures superior potency and safety in diverse preclinical tumor models with varying MSLN expression levels, positioning HBM9033 as a potential globally leading therapeutic option.
Source: prnasia.com
